On September 14, the FDA set aside four hours and invited more than 80 speakers to consider how psychedelic therapies might work in regulated settings. The discussion reflected growing interest from regulators, physicians, patients, and veterans’ organizations in how these potential treatments may offer relief to those living with mental illness. But it also revealed a gap beyond rescheduling or reclassification: the infrastructure needed to deliver these therapies safely and at scale.
It’s clear there is a significant patient need. More than 62 million American adults live with mental illness, and tens of millions have few, if any, treatments that work. Nearly one in three patients treated for major depressive disorder sees no meaningful relief from medication, and first-line post-traumatic stress disorder (PTSD) treatments carry an average nonresponse rate of 40%.
Psychedelic therapies could provide one of the solutions to this crisis. Findings from a 2022 trial published in the New England Journal of Medicine showed a single 25 mg dose of psilocybin, with psychological support, significantly reduced depressive symptoms in treatment-resistant patients. Similarly, Oregon Health & Science University published findings from the largest real-world U.S. study of psilocybin, including 346 people and 24 licensed service centers, with participants reporting reduced symptoms of depression, anxiety, and PTSD. Nearly two-thirds ranked the session among the most meaningful experiences of their lives.
Today’s psychedelics bear little resemblance to their 1970s counterparts. These medicines undergo rigorous clinical trials and licensed manufacturing processes to preserve safety, chain of custody, and their therapeutic effect. The clinical foundation has been established, and now the U.S. needs the operational foundation to act on it.
For these psychedelic therapies to reach patients and make an impact, more is involved than rescheduling and FDA approval. The commercial architecture – including manufacturing standards, licensed supply chains, clinical administration protocols, and trained practitioners – to deliver them safely and at scale has to be created.
As CEO and co-founder of Optimi Health, a Canada-based manufacturer and drug developer of pharmaceutical-grade psychedelic compounds for research and clinical use, I not only have a stake in this discussion, but also a unique understanding of how this can be achieved in real-world settings. Our company has spent several years manufacturing and exporting pharmaceutical-grade psychedelic therapies for clinical settings in Australia, Canada, and the United Kingdom.
Australia’s model offers key insights into how therapeutic delivery can work inside a national framework. There, when a patient with treatment-resistant depression sees an authorized psychiatrist, the psychiatrist then prescribes a pharmaceutical-grade dose from a licensed manufacturer. The patient then takes it under physician supervision and the chain of custody is documented at every step. There is no ambiguity about what was administered, at what dose, or by whom. Optimi has supported dozens of clinics in Australia, with no serious adverse events reported. And to-date we have supplied more than 5,000 doses of psychedelic therapies globally for patients and clinical research.
The recent FDA hearing and efforts from the Administration show that the U.S. is asking the right questions, and there’s an opportunity to build on this progress. The framework required to bring these therapies to American patients can be adapted from working models, with Canada and Australia already demonstrating that psychedelic medicines can be manufactured, distributed, and administered responsibly. As the largest and most innovative pharmaceutical market in the world, and with the American psychedelic drugs market forecasted to reach $3.60 billion by 2032, the U.S. has what it needs to build its own model and lead in this space. A great patient need can be met if pharmaceutical companies, and the government, are willing to take the next steps.
Veterans and millions of other Americans living with treatment-resistant mental illness are looking for solutions. The time is now for the U.S. to approve and reschedule psychedelic therapies and, most importantly, lay the right foundation for the next chapter in American mental healthcare and pharmaceutical industry innovation.
The opinions expressed in Fortune.com commentary pieces are solely the views of their authors and do not necessarily reflect the opinions and beliefs of Fortune.